Vanguard Group’s POINT Biopharma Global Inc. Common Stock PNT Stock Holding History

Vanguard Group’s Portfolio PNT Stock Details PNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-4,667,786	Closed	-$31.1M	–	4525
2023 Q3	$31.1M	Buy	4,667,786 +212,433	+5%	+$1.77M	﹤0.01%	2357
2023 Q2	$40.4M	Buy	4,455,353 +27,568	+0.6%	+$243K	﹤0.01%	2284
2023 Q1	$32.2M	Buy	4,427,785 +35,862	+0.8%	+$266K	﹤0.01%	2383
2022 Q4	$32M	Buy	4,391,923 +516,601	+13%	+$3.83M	﹤0.01%	2389
2022 Q3	$30M	Buy	3,875,322 +426,617	+12%	+$3.62M	﹤0.01%	2434
2022 Q2	$23.5M	Buy	3,448,705 +248,490	+8%	+$1.9M	﹤0.01%	2564
2022 Q1	$25.5M	Buy	3,200,215 +1,774,040	+124%	+$11.3M	﹤0.01%	2638
2021 Q4	$7.99M	Sell	1,426,175 -33,402	-2%	-$251K	﹤0.01%	3348
2021 Q3	$11.2M	Buy	+1,459,577	New	+$13.3M	﹤0.01%	3172

Other funds holding PNT

BTI

Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

Vanguard Group's PNT Position: Q4 2023 in Review

Vanguard Group sold out of POINT Biopharma Global Inc. Common Stock (PNT) in Q4 2023, closing a stake of 4,667,786 shares — an estimated $31.1M sold.

Vanguard Group first reported a position in PNT in Q3 2021 and held it in 9 quarters. The position peaked at $40.4M in Q2 2023. 1 fund tracked by Wall St. Rank holds PNT as of Q4 2023.

Vanguard Group reported no remaining POINT Biopharma Global Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
Vanguard Group sold 4,667,786 POINT Biopharma Global Inc. Common Stock shares in Q4 2023, an estimated $31.1M.
Vanguard Group first reported a position in POINT Biopharma Global Inc. Common Stock in Q3 2021 and held it in 9 quarters.
Vanguard Group's POINT Biopharma Global Inc. Common Stock position peaked at $40.4M in Q2 2023.
1 fund tracked by Wall St. Rank held POINT Biopharma Global Inc. Common Stock as of Q4 2023.

Based on Vanguard Group's 13F filing for Q4 2023, filed 14 Feb 2024.